Andrea Gaissler
Overview
Explore the profile of Andrea Gaissler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bopple K, Oren Y, Henry W, Dong M, Weller S, Thiel J, et al.
Cell Death Dis
. 2024 Apr;
15(4):290.
PMID: 38658567
High-grade serous ovarian cancer (HGSOC) represents the most common and lethal subtype of ovarian cancer. Despite initial response to platinum-based standard therapy, patients commonly suffer from relapse that likely originates...
2.
Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37286306
Background: The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the...
3.
Gaissler A, Sundebo Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, et al.
Front Immunol
. 2022 Jul;
13:906352.
PMID: 35874702
Immune checkpoint blockade (ICB) is standard-of-care for patients with metastatic melanoma. It may re-invigorate T cells recognizing tumors, and several tumor antigens have been identified as potential targets. However, little...
4.
Herold N, Schollhorn A, Feile A, Gaissler A, Mohrholz A, Pawelec G, et al.
Eur J Immunol
. 2022 Feb;
52(5):730-736.
PMID: 35133647
Conformational change of the β2 integrin lymphocyte function-associated antigen 1 (LFA-1) is an early marker of T cell activation. A protocol using the mAb clone m24 recognizing the active, extended...
5.
Bochem J, Zelba H, Spreuer J, Amaral T, Wagner N, Gaissler A, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34933966
Background: Anti-programmed cell death protein 1 (PD-1) antibodies are now routinely administered for metastatic melanoma and for increasing numbers of other cancers, but still only a fraction of patients respond....
6.
Kleih M, Bopple K, Dong M, Gaissler A, Heine S, Olayioye M, et al.
Cell Death Dis
. 2019 Nov;
10(11):851.
PMID: 31699970
Patients with high-grade serous ovarian cancer (HGSC) frequently receive platinum-based chemotherapeutics, such as cisplatin. Cisplatin binds to DNA and induces DNA-damage culminating in mitochondria-mediated apoptosis. Interestingly, mitochondrial DNA is critically...